Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1177-1181

  Farrell, David J ^a,c   Robbins, Marion ^a   Rhys Williams, William ^b   Love, William G ^b  

^a Quotient Bioresearch Ltd   (United Kingdom)

^b Destiny Pharma Ltd   (United Kingdom)

^c JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; FUSIDIC ACID; PSEUDOMONIC ACID; RETAPAMULIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN; XF 73;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DAPTOMYCIN; FUSIDIC ACID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MUPIROCIN; POLYMERASE CHAIN REACTION; PORPHYRINS; SEQUENCE ANALYSIS, DNA; VANCOMYCIN;

EID: 79952321538     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01285-10     Document Type: Article

References (36)

1. Al-Rawahi, G. N., et al. 2008. Community-associated CMRSA-10 (USA-300) is the predominant strain among methicillin-resistant Staphylococcus aureus strains causing skin and soft tissue infections in patients presenting to the emergency department of a Canadian tertiary care hospital. J. Emerg. Med. 38:6-11.
2. Bode, L. G., et al. 2010. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N. Engl. J. Med. 362:9-17.
3. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.
4. Bogdanovich, T., et al. 2007. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents. Antimicrob. Agents Chemother. 51:4191-4195.
5. Centers for Disease Control and Prevention. MRSA in healthcare settings. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/ ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf.
6. Clark, C., et al. 2009. Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs. Antimicrob. Agents Chemother. 53:1353-1361.
7. Clark, C., et al. 2009. Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 53:3118-3121.
8. Clinical and Laboratory Standards Institute (CLSI). 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard - seventh edition, M7-A7. CSLI, Wayne, PA.
9. Cuevas, O., et al. 2007. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Spain: a multicentre prevalence study (2002). Clin. Microbiol. Infect. 13:250-256.
10. Farrell, D. J., M. Robbins, W. Rhys-Williams, and W. G. Love. 2010. In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species. Int. J. Antimicrob. Agents 35:531-536.
11. Friedman, L., J. D. Alder, and J. A. Silverman. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145.
12. Gentry, D. R., S. F. Rittenhouse, L. McCloskey, and D. J. Holmes. 2007. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob. Agents Chemother. 51:2048-2052.
13. Gentry, D. R., et al. 2008. Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus. Antimicrob. Agents Chemother. 52:4507-5409.
14. Gonzalez, B. E., et al. 2006. Community-associated strains of methicillin-resistant Staphylococcus aureus as the cause of healthcare- associated infection. Infect. Control Hosp. Epidemiol. 27:1051-1056.
15. Health Protection Agency. 2007. Surveillance of healthcare associated infections report 2007. Health Protection Agency, London, United Kingdom. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1196942169446.
16. Hobbs, J. K., K. Miller, A. J. O'Neill, and I. Chopra. 2008. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J. Antimicrob. Chemother. 62:1003-1008.
17. Jones, R. N., T. R. Fritsche, H. S. Sader, and J. E. Ross. 2006. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob. Agents Chemother. 50:2583-2586.
18. Kauffman, C. A., et al. 1993. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am. J. Med. 94:371-378.
19. King. M. D., et al. 2006. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144:309-317.
20. Kosowska-Shick, K., et al. 2006. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 50:765-769. (Pubitemid 43190997)
21. Kosowska-Shick, K., et al. 2009. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 53:4217-4224.
22. Kourbatova, E. V., et al. 2005. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am. J. Infect. Control 33:385-391.
23. Laupland, K. B., and J. M. Conly. 2003. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin. Infect. Dis. 37:933-938.
24. Miller, M. A., A. Dascal, J. Portnoy, and J. Mendelson. 1996. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect. Control Hosp. Epidemiol. 17:811-813.
25. Moran, G. J., et al. 2006. EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
26. Ooi, N., K. Miller, W. Rhys-Williams, W. G. Love, and I. Chopra. 2009. Comparison of bacterial membrane active novel porphyrin and metalloporphyrin antimicrobials. Clin. Microbiol. Infect. 15:S287-S288.
27. Ooi, N., et al. 2009. XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. J. Antimicrob. Chemother. 64:735-740.
28. Ooi, N., et al. 2010. XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J. Antimicrob. Chemother. 65:72-78.
29. Seybold, U., et al. 2006. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 42:647-656.
30. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
31. Simor, A. E., et al. 2007. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob. Agents Chemother. 51:3880-3886.
32. Traczewski, M. M., and S. D. Brown. 2008. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob. Agents Chemother. 52:3863-3867.
33. Trautmann, M., J. Stecher, W. Hemmer, K. Luz, and H. T. Panknin. 2008. Intranasal mupirocin prophylaxis in elective surgery. A review of published studies. Chemotherapy 54:9-16.
34. Upton, A., S. Lang, and H. Heffernan. 2003. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J. Antimicrob. Chemother. 51:613-617.
35. van Rijen, M. M., M. Bonten, R. P. Wenzel, and J. A. Kluytmans. 2008. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J. Antimicrob. Chemother. 61:254-261.
36. Vivoni, A. M., et al. 2005. Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect. Control Hosp. Epidemiol. 26:662-667.